Retinoblastoma Treatment Market Outlook:
Retinoblastoma Treatment Market size was over USD 2.48 billion in 2025 and is projected to reach USD 3.78 billion by 2035, witnessing around 4.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of retinoblastoma treatment is evaluated at USD 2.58 billion.
The market is experiencing a notable surge propelled by significant advancements in targeted therapies. Traditional treatment modalities such as surgery, chemotherapy, and radiation have shown efficacy, but the landscape is evolving with the advent of more precise and targeted approaches. Targeted therapies offer a tailored and focused attack on cancer cells, minimizing damage to surrounding healthy tissues. Targeted therapies are at the forefront of a paradigm shift in cancer treatment, including retinoblastoma. These therapies are designed to identify and attack specific molecules or pathways involved in the growth and survival of cancer cells. According to a report, the global targeted therapy sales were valued at USD 136 billion in 2020.
One of the key advantages of targeted therapies is their ability to minimize collateral damage to healthy cells. Unlike traditional treatments that broadly impact rapidly dividing cells, including healthy ones, targeted therapies aim at specific genetic or molecular abnormalities unique to cancer cells. Retinoblastoma is a rare form of eye cancer that primarily affects young children. Treatment options include surgery, chemotherapy, radiation therapy, or a combination of these approaches.
